| Alexandria Real Estate Equities, Inc. | |||
| Ticker: | ARE | 251 South Lake Avenue, Suite 700 | |
| Exchange: | New York Stock Exchange | Pasadena, CA 91101 | |
| Industry: | Financial (SIC Code 6798) | (213) 687-5000 | |
| Type of Shares: | Common Shares | Filing Date: | 3/18/97 | |
| U.S. Shares: | 6,750,000 | Offer Date: | 5/28/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $20.00 - $22.00 | |
| Primary Shares: | 6,750,000 | Offer Price: | $20.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.30 | |
| Offering Amount: | $141,750,000 | Selling: | $0.77 | |
| Expenses: | - | Reallowance: | $0.10 | |
| Shares Out After: | 10,829,634 |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Everen Securities, Inc. | Co-manager | (312) 574-6859 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| Smith Barney Inc. | Co-manager | (212) 723-7300 |
| Issuer's Law Firm: | Skadden, Arps, Slate, Meagher & Flom |
| Bank's Law Firm: | Goodwin Procter & Hoar |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $17.67 | Assets: | $160.39 | ||
| Net Income: | $0.92 | Curr Assets: | |||
| EPS: | Liabilities: | $120.82 | |||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$1.65 | Equity: | $39.57 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a REIT. The company was formed in October 1994 to acquire, manage, expand and selectively develop high quality, strategically located office properties containing office and laboratory space designed and improved for lease. The offices are principally leased to pharmaceutical, biotechnology, diagnostic and personal care products companies, major scientific research institutions and related government agencies. The company's tenant base is broad and diverse within the Life Science Industry and reflects the company's focus on regional, national and international tenants with substantial financial and operational resources. Significant tenants include affiliates of major pharmaceutical companies; biotechnology companies and their affiliates; affiliates of personal care products companies; major scientific research institutions; clinical laboratories; and governmental agencies. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay a portion of the company's outstanding indebtedness, to acquire the Acquisition LLC, and for general corporate purposes. |